Suzanne Vernon

Suzanne D. Vernon, PhD, is the Research Liaison at Bateman Horne Center of Excellence which specializes in treatment and research for ME/CFS and Fibromyalgia and the Chief Scientific Revolutionary of The BioCollective, a collaborative that provides storage and sales of microbiome samples for research and development.

From November 2007 – May 2015, Dr. Vernon was the Scientific Director of Solve ME/CFS Initiative, formerly known as CFIDS Association of America. While there she recognized that access to well-characterized clinical populations was a barrier to engaging more scientists in ME/CFS research. Thus, she started the Research Institute Without Walls (RIWW), "the first nonprofit patient-centered research initiative focused on identifying diagnostic biomarkers and disease-modifying treatment for ME/CFS." The core of RIWW is the SolveCFS BioBank & Patient Registry.

From May 1990 – October 2007, Dr. Vernon worked for the US Centers for Disease Control, first on the team investigating the human papillomavirus as an opportunistic infection in HIV-infected woman, and then in 1997, she became the CFS research group team leader, under William Reeves, MD, the Director of the CDC Chronic Fatigue Research Program.

In 2005, Dr Vernon was one of the authors of the CDC case definition of CFS, commonly called the Reeves criteria, which has garnered much criticism for not being specific enough to exclude patients which other illnesses. In particular, there is no mention of post-exertional malaise.

Talks and interviews

 * 2016, Precision Medicine for ME/CFS & Fibromyalgia
 * 2015, Sleep and ME/CFS - Suzanne Vernon, PhD, A Bateman Horne Education Meeting
 * 2015, [[Spoonie Radio] Episode 09 Guest - Dr. Suzanne Vernon Podcast and Full Text Transcript]
 * 2014, Episode 70, [[ME/CFS Alert] - Llewellyn King Interviews Dr. Suzanne Vernon]
 * 11 April 2012, "Cognition & CFS: What Do We Know?" by the CFIDS Association of America with speakers Gudrun Lange and Suzanne Vernon, introduced by Kim McCleary

Studies and Articles

 * 2017, Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (Full Text)
 * 2017, Neural Consequences of Post-Exertion Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (Full Text)
 * 2016, The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome (Full Text)
 * 2016, Tracking post-infectious fatigue in clinic using routine Lab tests (Full Text)
 * 2016, Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey (Abstract)
 * 2016, Uncovering Biomarkers– Fcg receptors in ME/CFS
 * 2016, Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome (Full Text)
 * 2015, Chronic fatigue syndrome versus systemic exertion intolerance disease] (Abstract)
 * 2015, Comparing and contrasting consensus versus empirical domains (Abstract)
 * 2015, Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (Full Text)
 * 2014, Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis
 * 2012, Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue
 * 2006, Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study (Abstract)
 * 2006, Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus (Full Text)
 * 2005, Chronic Fatigue Syndrome – A clinically empirical approach to its definition and study.
 * 2003, Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution (Full Text)

Online presence

 * Twitter
 * LinkedIn

Learn more

 * Profile